1STAHL S M. Prophylactic antipsyehotics: do they keep you from catching schizophrenia? [ J ] . J Clin Psychiatry, 2004,65 ( 11 ) : 1445 - 1446.
2FINDLING R L, STEINER H, WELLER E B. Use of antipsychotics in children and adolescents[ J] . J Clin Psychiatry, 2005, 66( Suppl 7) :29 -40.
3SCHOOLER N R. Relapse prevention and recovery in the treatment of schizophrenia[ J] . J Clin Psychiatry, 2006, 67 ( Suppl 5 ) : 19 - 23.
4MCEVOY J P. Risks versus benefits of different types of long-acting injectable antipsychotics [ J ] . J Clin Psychiatry, 2006, 67 ( Suppl 5): 15-18.
5BLIER P, HABIB R, FLAMENT M F. Pharmacotherapies in the management of obsessive-compulsive disorder [ J ] Can J Psychiatry, 2006, 51(7):417-430.
6DENYS D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders[ J] . Psychiatr Clin N Am, 2006,29 ( 2 ) :553 - 584.
7CANADIAN PSYCHIATRIC ASSOCIATION. Clinical practice guidelines management of anxiety disorders ( 6 ) obsessive-compulsive disorder[ J] . Can J Psychiatry, 2006, 51 ( Suppl 2) :43 - 50.
8DILER R S, YOLGA A, AVCI A , et al. Risperidone-induced obsessive-compulsive symptoms in two children[ J] . J Child Adolesc Psychopharmacol, 2003,13 ( Suppl 1 ) : 89 - 92.
9DENYS D, ZOHAR J, WESTENBERG H G. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence [J] . J Clin Psychiatry, 2004, 65(Suppl 14) : 11 - 17.
10STAHL S M. Anticonvulsants as mood stabilizers and adjuncts to antipsychotics : valproate, lamotrigine , carbamazepine, and oxcarbazepine and actions at voltage-gate sodium channels [ J ] . J Clin Psychiatry,2004,65(6) : 738 -739.
